AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00000463
Drug: lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03650205
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule.
Trial: NCT01961830
Drug: ME1100 inhalation solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00286143
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl is added to epidural Bupivacaine to be administered to neonates having thoracotomy for lung resections.
Trial: NCT03029208
Drug: Iron therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron therapy will be administered if ferritin is \<=100 ng/mL and/or TSAT is \<=20%.
Trial: NCT01700946
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: given intravenously
Trial: NCT01700946
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: given intrathecally or intravenously
Trial: NCT01700946
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: given orally
Trial: NCT01700946
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given intrathecally
Trial: NCT02211989
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01070810
Drug: Thiamine
RxNorm normalized name: Thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiamine 200mg in 50ml D5W
Trial: NCT05002101
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with weight more than 10 kg were asked to take 5 ml syrup daily, while children with weight less than 10 kg were asked to take 2.5 ml daily.
Trial: NCT01132079
Drug: cream treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01182077
Drug: ASP015K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01813019
Drug: AFQ056
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mGluR5 antagonist
Trial: NCT01813019
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT01543269
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of Placebo in fasting condition with 240±10 ml of water at sitting position in ambient temperature.
Trial: NCT03352115
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 day course of oral prednisolone
Trial: NCT03352115
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo syrup
Trial: NCT05090449
Drug: Chlorthalidone (HIGROTON® 50)
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets with 50mg of Chlorthalidone, product de Sandoz, S.A. de C.V.
Trial: NCT05090449
Drug: A1+ A2 Co-administration of Chlorthalidone and Losartan
RxNorm normalized name: Atenolol and Chlorthalidone Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg chlorthalidone + 100 mg losartan potassium
Trial: NCT05090449
Drug: Chlorthalidone + Losartan Fixed-Dose combination
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets with fixed combination of Chlorthalidone 25 mg and Losartan Potassium
Trial: NCT03965052
Drug: Travatan 0.004 % Ophthalmic Solution
RxNorm normalized name: Travatan 0.004 % Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Generic name: Travoprost~* Distinctive denomination: Travatan®~* Active ingredients: Travoprost 0.004%~* Pharmaceutical form: Ophthalmic solution.~* Presentation: multi-dose dropper bottle, 2.5 milliliters.~* Prepared by: Alcon Laboratories Inc.~* Description of the solution: transparent solution, free of visible particles.~* Consult information to prescribe.
Trial: NCT00761059
Drug: Glucose 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The oral application of 0,3 ml/kg Glucose 20% 3 minutes before nasopharyngeal suctioning
Trial: NCT03970109
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet
Trial: NCT02322697
Drug: Intravenous administration of L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic intravenous administration of L-carnitine (1000mg on each dialysis session) for 1 year in hemodialysis patients
Trial: NCT01313572
Drug: Adenosine SPECT-MPI
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute
Trial: NCT03221257
Drug: Placebo (Plac)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a Plac, matched to resemble PFD, titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).
Trial: NCT03519230
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60mg BID, PO
Trial: NCT04208412
Drug: KVD900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KVD900 tablet 600 mg
Trial: NCT01347203
Drug: DPOC-4088
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation A = 16 hr release formulation)
Trial: NCT01347203
Drug: DPOC-4088
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation A = 16 hr release formulation)
Trial: NCT01347203
Drug: DPOC-4088
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation B = 20 hr release formulation)
Trial: NCT01347203
Drug: DPOC-4088
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation B = 20 hr release formulation)
Trial: NCT01196728
Drug: CM3.1-AC100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAD study with single ascending subcutaneous doses
Trial: NCT04666441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV or SC single dose to match
Trial: NCT00298038
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01823393
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valvuloplasty is performed in a conventional manner, ie with an injection of unfractionated heparin (50 IU / kg) at the start of procedure
Trial: NCT00389818
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 IV Day 1 of each cycle
Trial: NCT00389818
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/m2 IV Day 1 of each cycle
Trial: NCT02710526
Drug: CAM2038
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-Acting Subcutaneous Injectable Depot of Buprenorphine
Trial: NCT00499369
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00499369
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01626976
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution, single dose
Trial: NCT01626976
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suspension, single dose
Trial: NCT01818336
Drug: Penicillin skin test kit
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergy skin testing is done by puncture and intradermal. If all tests negative, subjects receive an oral amoxicillin challenge.
Trial: NCT02305940
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An oral dose of 100 mg of Doxycycline once daily, for a total duration of 52 weeks.
Trial: NCT02305940
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An oral dose of one capsule of placebo once daily, for a total duration of 52 weeks
Trial: NCT03258476
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule
Trial: NCT03195413
Drug: 1:1 volume measured solution of: 1% lidocaine without epinephrine and 0.5% bupivacaine without epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is the anesthetic solution that will be administered during the ultrasound-guided nerve block
Trial: NCT01055392
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo tablets were administered twice-a-day for two years.
Trial: NCT05038059
Drug: ethanolic extract of sapindus mukorossi
RxNorm normalized name: Sapindus mukorossi whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ethanolic extract will be used as final endodontic irrigant during root canal procedures in extracted teeth.
Trial: NCT05038059
Drug: ethylene diamine tetra acetic acid
RxNorm normalized name: Ethylene-diamine
DrugBank: Ethylenediamine (DB14189)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: used as final endodontic irrigant in root canal therapy
Trial: NCT04011475
Drug: Other LABA/LAMA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiotropium/olodaterol, indacaterol/glycopyrronium, vilanterol/umeclidinium
Trial: NCT00760279
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02329405
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00126048
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT02192684
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compare with pioglitazone
Trial: NCT01607905
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 500 mg (in Cycle 1, Week 1) to 1000 mg (in Cycle 1, Week 2 and onwards) of acetaminophen will be administered 1 hour prior to each selinexor dose up to 8 doses per cycle (28 days per cycle)
Trial: NCT00000435
Drug: None-placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo was taken in pill form at 25mg/day for 6 months
Trial: NCT01917045
Drug: Sufentanil (R30730, brand name Sufenta)
RxNorm normalized name: sufentanil Injection [Sufenta]
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sufentanil 1ug/ml
Trial: NCT02284828
Drug: BIA 2-093
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01428492
Drug: GSK2110183
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The oral, once daily dose of GSK2110183 will be dependent on the cohort to which a subject is assigned. Subjects enrolled in Cohort 1 will receive 75 mg GSK2110183 once daily. Dose escalation in Schedule A and Schedule B will follow 25 mg increments in a 3+3 dose escalation procedure up to a maximum of 150mg daily or until MTD is reached, whichever comes first, for each schedule. GSK2110183 will continue at daily dosing until treatment discontinuation criteria is met.
Trial: NCT03773744
Drug: Ad-MAGEA3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenovirus vaccine expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen
Trial: NCT03773744
Drug: MG1-MAGEA3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MG1 Maraba oncolytic virus expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen
Trial: NCT03773744
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: low-dose chemotherapy
Trial: NCT02193620
Drug: Placebo soft capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose of oral Placebo soft capsules, initial dose: 2 capsules, then 1 capsule; t.i.d.
Trial: NCT02193620
Drug: Dicofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive diclofenac by IM injection for analgesia as rescue pain control.
Trial: NCT02991209
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02991209
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03708341
Drug: Melatonin 5 mg
RxNorm normalized name: melatonin 5 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Systematic daily administration of melatonin 5 mg during patient's ICU stay
Trial: NCT03708341
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic daily administration of placebo during patient's ICU stay
Trial: NCT02647151
Drug: METHYLAMINOLEVULINATE HYDROCHLORIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.~skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed.
Trial: NCT02106338
Drug: CRS3123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRS3123, a methionyl-tRNA synthetase inhibitor, formulated in 100 and 200 mg capsules; 8 subjects randomized in Cohorts A through C receive doses of 200 mg, 400 mg; and 600 mg or 100mg are planned respectively given orally every 12 hours for 10 days.
Trial: NCT04498884
Drug: Rinsulin® mix 30/70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one subcutaneous injection at a dose of 0.4 IU/kg
Trial: NCT04498884
Drug: Humulin® M3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one subcutaneous injection at a dose of 0.4 IU/kg
Trial: NCT00094380
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00226941
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is a cancer medication, and is administered based on m² of body surface area (BSA) delivered in equivalent morning and evening doses
Trial: NCT00928317
Drug: ART621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0mg/kg s.c.
Trial: NCT00928317
Drug: ART621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5mg/kg s.c.
Trial: NCT00928317
Drug: ART621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75mg/kg s.c.
Trial: NCT00928317
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo s.c.
Trial: NCT02966080
Drug: HEP-IV
RxNorm normalized name: heparin sodium, porcine Injectable Solution [Hep-Pak]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04840095
Drug: Ketones
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sports supplement that is administered mid-scan.
Trial: NCT00002526
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00486343
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets 2x600mg BID for 24 weeks
Trial: NCT00659269
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are treated per standard of care according to the choice of the treating physician with heavy metals (cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), or vinca alkaloids (vincristine, vinorelbine)~Ranges of cumulative doses (in mg/m2) are:~paclitaxel, 700-960; docetaxel, 240-400; vincristine, 8-16; vinorelbine, 360-480; cisplatin, 240-400; oxaliplatin, 400-800; abraxane, 1200-1800
Trial: NCT02265705
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03850886
Drug: Antidiabetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin or Sulphonylurea
Trial: NCT01877421
Drug: 2 mg KSL-W
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01877421
Drug: 4 mg KSL-W
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01877421
Drug: 6 mg KSL-W
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01877421
Drug: 10 mg KSL-W
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01877421
Drug: 20 mg KSL-W
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01877421
Drug: 30 mg KSL-W
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01877421
Drug: 50 mg KSL-W
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01877421
Drug: 75 mg KSL-W
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01877421
Drug: 100 mg KSL-W
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01141296
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill identical to active drug will be given PO once a day for 1 year
Trial: NCT00781326
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given in doses matching those of nimodipine.
Trial: NCT01030224
Drug: AZD9742
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing single IV infusion doses of AZD9742 given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo). Specific doses will be selected by the safety review committee
Trial: NCT01030224
Drug: Placebo to match AZD9742
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV infusion of AZD9742 placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo)
Trial: NCT00647231
Drug: HKT-500 Topical Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with Ketoprofen Topical Patch
Trial: NCT02647151
Drug: AMINOLEVULINIC ACID HYDROCHLORIDE
RxNorm normalized name: Aminolevulinic Acid Hydrochloride
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.~skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed.
Trial: NCT00793910
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (sugar pill) taken by mouth thrice daily for 7 days
Trial: NCT02308202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01491243
Drug: Standard treatment with saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. 1 ml/kg/h saline infusion for 48 h in case of abnormal NGAL findings
Trial: NCT01525082
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine by mouth twice daily on Days 1 to 14
Trial: NCT01702233
Drug: Traumeel S inj
RxNorm normalized name: Traumeel S Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traumeel S inj. 2 ml. subacromial 3 times at days 1, 8 and 15
Trial: NCT01702233
Drug: Saline inj
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline inj. 2 ml. subacromial 3 times at days 1, 8 and 15
Trial: NCT01564225
Drug: EDI200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1 will be dosed at 3 mg/kg/dose. Cohort 2 will be dosed at 10 mg/kg/dose. Both cohorts will receive 2 doses/week for a total of 5 doses.
Trial: NCT00799812
Drug: CHG 2% w/v & IPA 70% v/v, swabstick (3 @ once).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 swabsticks topically applied at the same time to intact skin
Trial: NCT00799812
Drug: CHG 2% w/v & IPA 70% v/v swab applied sequentially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gluconate 2% w/v and isopropyl alcohol 70% v/v; 3 swabsticks applied sequentially to intact skin.
Trial: NCT00799812
Drug: Aqueous CHG 4% w/v applied according to mfr's directions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gluconate 4% w/v in an aqueous base applied according to mfr's directions. Step 1) 5 ml of Hibiclens applied to a sterile gauze pad. Step 2) Product applied to treatment area on intact skin for 2 minutes. Area dried with sterile towel or sterile gauze. Steps 1 and 2 repeated.
Trial: NCT00004317
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: See arm descriptions